Telaprevir (brand name Incivek) is a medication used to treat chronic hepatitis C virus (HCV) infection. It is a protease inhibitor, which works by blocking the protease enzyme that helps to make new HCV. Telaprevir is used in combination with other medications, such as peginterferon and ribavirin, to treat chronic HCV genotype 1 infection in adults. Common side effects include nausea, headache, fatigue, and rash.
Telaprevir is a medication used to treat chronic Hepatitis C infection, specifically genotype 1, in combination with other antiviral medications [1, 2]. It belongs to a class of drugs called direct-acting antivirals (DAAs) [2].
Here's how Telaprevir works: The Hepatitis C virus (HCV) has a specific enzyme, NS3/4A protease, that's crucial for the virus to replicate. Telaprevir acts as an inhibitor, binding to this enzyme and preventing the virus from reproducing [1, 2]. This helps reduce the amount of virus in the body and improves the chance of eliminating the infection completely.
However, it's important to note that Telaprevir is no longer widely used in current treatment regimens. While it was a significant advancement in HCV treatment when it was approved in 2011, newer DAAs have emerged that offer several advantages [3, 5]. These newer medications have higher cure rates, fewer side effects, and are easier to administer than Telaprevir-based treatments [5].
Here's a summary of some key points about Telaprevir:
- Use: In combination with other medications to treat chronic Hepatitis C genotype 1 infection (not used alone) [1].
- Class: Direct-acting antiviral (DAA) [2].
- Mechanism of action: Inhibits the NS3/4A protease enzyme of HCV, preventing viral replication [1, 2].
- Current use: No longer widely used due to availability of more effective DAAs with better tolerability [3, 5].